AstraZeneca is removing its Covid vaccine worldwide, months after the pharmaceutical giant admitted that it can cause a rare and dangerous side effect.
The jab, developed by Oxford University , can no longer be used in the European Union after the company voluntarily withdrew its 'marketing authorisation', coming into effect today.
AstraZeneca admitted in February that the vaccine can, in very rare cases, cause Thrombosis with Thrombocytopenia Syndrome - which has been linked to more than 80 deaths in Britain as well as hundreds of serious injuries. The company said in court documents that the vaccine is reportedly no longer being manufactured or supplied, having been superseded by updated vaccines that tackle newer variants.
'Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic.
News Astrazeneca European Union Oxford University
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Dad who suffered brain injury days after getting COVID vaccine sues AstraZenecaJamie Scott alleges the pharmaceutical giant exaggerated the vaccine's effectiveness and downplayed its risks. AstraZeneca denies the claims made against them.
Read more »
Q&A: AstraZeneca's COVID-19 vaccine and blood clots—what you need to knowPharmaceutical giant AstraZeneca admitted in court this week that its COVID-19 vaccine can cause a rare but deadly blood-clotting condition that has become the central focus of a class-action lawsuit worth potentially $125 million.
Read more »
AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay dealThe update came ahead of AstraZeneca’s annual general meeting on Thursday afternoon.
Read more »
AstraZeneca Promises to Raise Dividend Amid Concerns About UK CompetitivenessThe drugmaker AstraZeneca (AZ) has announced a 7% increase in its annual dividend, highlighting its confidence in performance and cash generation. The timing of the announcement, just before the annual general meeting, raises concerns about the UK's competitiveness as a business destination.
Read more »
AstraZeneca profit up on strong sales of cancer drugsBritish pharmaceutical giant AstraZeneca on Thursday said net profit jumped 21 percent in the first three months of the year thanks to strong growth in sales of cancer drugs.
Read more »